Abstract
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Current Pharmaceutical Design
Title: Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Volume: 11 Issue: 2
Author(s): Ritu Saini, William D. Tutrone and Jeffrey M. Weinberg
Affiliation:
Keywords: psoriasis, biologic therapy, t cell, cytokine, infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene
Abstract: Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European population. Over the last several years, one of the major focuses in psoriasis research has been the development of biologic therapies for this disease. The aim of these therapies is to provide selective, immunologically directed intervention with fewer side effects than traditional therapies. The goal of this article is to review the progress of the biologic agents which are available, or under investigation for clinical use: infliximab, etanercept, efalizumab, alefacept, and adalimumab. In addition, two other investigational therapies, oral tazarotene and oral pimecrolimus will be discussed. Clinical data for these agents, including the most recent phase II and / or III study results, will be discussed, as well as the most recent safety data
Export Options
About this article
Cite this article as:
Saini Ritu, Tutrone D. William and Weinberg M. Jeffrey, Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382232
DOI https://dx.doi.org/10.2174/1381612053382232 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension: Basics Concepts and the Evolving Role of Novel Treatments
Current Hypertension Reviews New Biological Approaches in Asthma: DNA-Based Therapy
Current Medicinal Chemistry Vasopressin and Oxytocin in Control of the Cardiovascular System
Current Neuropharmacology Neurologic Sequelae in Critical Illness: Evaluation and Outcomes
Current Respiratory Medicine Reviews Animal Models for the Development of New Neuropharmacological Therapeutics in the Status Epilepticus
Current Neuropharmacology Sodium Benzenesulfinates: Novel and Effective Organo Catalyst for Three Component Synthesis 5,6,7,8-Tetrahydro-4H-chromene Derivatives Under Ultrasound Irradiation
Letters in Organic Chemistry Fibromyalgia
Current Rheumatology Reviews Evaluation of Selected Natural Compounds as Dual Inhibitors of Catechol-O-Methyltransferase and Monoamine Oxidase
Central Nervous System Agents in Medicinal Chemistry Vaccine Development for Group A Streptococcus Infections and Associated Diseases
Current Drug Targets Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Should STEMI Patients Receive Opiate Analgesia? The Morphine Paradox
Current Vascular Pharmacology Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Enantiomeric Local Anesthetics: Can Ropivacaine and Levobupivacaine Improve Our Practice?
Current Drug Therapy Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Are the Long-Acting Intramuscular Formulations of Risperidone or Paliperidone Palmitate Associated with Post-Injection Delirium/Sedation Syndrome? An Assessment of Safety Databases
Current Drug Safety Crosslinked, Polymerized, and PEG-Conjugated Hemoglobin-Based Oxygen Carriers: Clinical Safety and Efficacy of Recent and Current Products
Current Drug Discovery Technologies Design, Synthesis, Pharmacological Evaluation and Descriptor Based Similarities Study of N,N-diphenyl-2-[4-(substituted phenyl)piperazin-1- yl]acetamides as Potential Antipsychotics
Medicinal Chemistry Antioxidant Nanoplatforms for Dermal Delivery: Melatonin
Current Drug Metabolism